FMP
Adial Pharmaceuticals, Inc.
ADIL
NASDAQ
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
1.07 USD
0.055 (5.16%)
About
ceo
Mr. Cary John Claiborne MBA
sector
Healthcare
industry
Biotechnology
website
https://www.adialpharma.comexchange
NASDAQ
Description
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
CIK
0001513525
ISIN
US00688A2050
CUSIP
00688A106
Address
1180 Seminole Trail
Phone
434 422 9800
Country
US
Employee
4
IPO Date
Jul 27, 2018
Key Executives
